Hideaki Izumi

Sendai, 9808574, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Author Correction: Low-energy shock wave therapy ameliorates ischemic-induced overactive bladder in a rat model.

Author Correction: Low-energy shock wave therapy ameliorates ischemic-induced overactive bladder in a rat model.

Journal: Scientific reports

Published: July 26, 2023

Low-energy shock wave therapy ameliorates ischemic-induced overactive bladder in a rat model.

Low-energy shock wave therapy ameliorates ischemic-induced overactive bladder in a rat model.

Journal: Scientific reports

Published: May 24, 2022

Improvement of Cardiac Function by Laparoscopic Adrenalectomy in a Patient with Severe Heart Failure Attributable to Primary Aldosteronism.

Improvement of Cardiac Function by Laparoscopic Adrenalectomy in a Patient with Severe Heart Failure Attributable to Primary Aldosteronism.

Journal: The Tohoku journal of experimental medicine

Published: May 17, 2019

Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model.

Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model.

Journal: The Prostate

Published: October 29, 2018

Infliximab-Induced Tubulointerstitial Nephritis with Image Findings of Striated Nephrogram in Crohn's Disease.

Infliximab-Induced Tubulointerstitial Nephritis with Image Findings of Striated Nephrogram in Crohn's Disease.

Journal: The Tohoku journal of experimental medicine

Published: July 06, 2018

High luteinizing hormone weakens urinary continence mechanisms in association with prostaglandin E2 elevation in a postmenopausal rat model.

High luteinizing hormone weakens urinary continence mechanisms in association with prostaglandin E2 elevation in a postmenopausal rat model.

Journal: Neurourology and urodynamics

Published: September 19, 2017

Phosphodiesterase type 5 inhibitor administered immediately after radical prostatectomy temporarily increases the need for incontinence pads, but improves final continence status.

Phosphodiesterase type 5 inhibitor administered immediately after radical prostatectomy temporarily increases the need for incontinence pads, but improves final continence status.

Journal: Investigative and clinical urology

Published: July 22, 2016

Impact of Tissue Sealing Sheet on Erectile Dysfunction in a Rat Model of Nerve-Sparing Radical Prostatectomy.

Impact of Tissue Sealing Sheet on Erectile Dysfunction in a Rat Model of Nerve-Sparing Radical Prostatectomy.

Journal: The journal of sexual medicine

Published: June 12, 2016

Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer.

Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer.

Journal: Molecular and clinical oncology

Published: April 09, 2016

Urinary straining contributes to inguinal hernia after radical retropubic prostatectomy.

Urinary straining contributes to inguinal hernia after radical retropubic prostatectomy.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: October 14, 2015

Effects of phosphodiesterase type 5 inhibitor, tadalafil, on continence reflex in rats.

Effects of phosphodiesterase type 5 inhibitor, tadalafil, on continence reflex in rats.

Journal: International urogynecology journal

Published: April 06, 2014

A case of papillary renal cell carcinoma mimicking a hemorrhagic renal cyst

A case of papillary renal cell carcinoma mimicking a hemorrhagic renal cyst

Journal: Hinyokika kiyo. Acta urologica Japonica

Published: January 19, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026